single dose Sildenafil

Phase 3Small molecule

UUdo Sechtem

single dose Sildenafil is one of 3 small molecule programs targeting Coronary Vasospasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary VasospasmActive, not recruiting

Coronary VasospasmPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Coronary Vasospasm

#DrugCompanyPhaseTrials

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—2

Viagra

VViatris Specialty LLC

Approved

—3

single dose Sildenafil

UUdo Sechtem

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coronary Vasospasm1 trial

Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm

Withdrawn·UUdo Sechtem·Phase 3·NCT00454714

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for single dose Sildenafil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — single dose Sildenafil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for single dose Sildenafil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Udo Sechtem company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUdo Sechtem

single dose Sildenafil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coronary Vasospasm1 trial

References

Drug Info

Quick Facts

Related News